Your browser doesn't support javascript.
loading
Navigating Precision Oncology: Insights from an Integrated Clinical Data and Biobank Repository Initiative across a Network Cancer Program.
Aryal, Bibek; Bizhanova, Zhadyra; Joseph, Edward A; Yin, Yue; Wagner, Patrick L; Dalton, Emily; LaFramboise, William A; Bartlett, David L; Allen, Casey J.
Afiliación
  • Aryal B; Allegheny Singer Research Institute, Allegheny Health Network, Pittsburgh, PA 15212, USA.
  • Bizhanova Z; Allegheny Singer Research Institute, Allegheny Health Network, Pittsburgh, PA 15212, USA.
  • Joseph EA; Allegheny Singer Research Institute, Allegheny Health Network, Pittsburgh, PA 15212, USA.
  • Yin Y; Allegheny Singer Research Institute, Allegheny Health Network, Pittsburgh, PA 15212, USA.
  • Wagner PL; Division of Surgical Oncology, Institute of Surgery, Allegheny Health Network, Pittsburgh, PA 15212, USA.
  • Dalton E; Illumina, San Diego, CA 92122, USA.
  • LaFramboise WA; Pathology, Allegheny General Hospital, Pittsburgh, PA 15212, USA.
  • Bartlett DL; Allegheny Health Network Cancer Institute, Pittsburgh, PA 15212, USA.
  • Allen CJ; Division of Surgical Oncology, Institute of Surgery, Allegheny Health Network, Pittsburgh, PA 15212, USA.
Cancers (Basel) ; 16(4)2024 Feb 12.
Article en En | MEDLINE | ID: mdl-38398150
ABSTRACT
Advancing cancer treatment relies on the rapid translation of new scientific discoveries to patient care. To facilitate this, an oncology biobank and data repository program, also referred to as the "Moonshot" program, was launched in 2021 within the Integrated Network Cancer Program of the Allegheny Health Network. A clinical data program (CDP) and biospecimen repository were established, and patient data and blood and tissue samples have been collected prospectively. To date, the study has accrued 2920 patients, predominantly female (61%) and Caucasian (90%), with a mean age of 64 ± 13 years. The most common cancer sites were the endometrium/uterus (12%), lung/bronchus (12%), breast (11%), and colon/rectum (11%). Of patients diagnosed with cancer, 34% were diagnosed at stage I, 25% at stage II, 26% at stage III, and 15% at stage IV. The CDP is designed to support our initiative in advancing personalized cancer research by providing a comprehensive array of patient data, encompassing demographic characteristics, diagnostic details, and treatment responses. The "Moonshot" initiative aims to predict therapy responses and clinical outcomes through cancer-related biomarkers. The CDP facilitates this initiative by fostering data sharing, enabling comparative analyses, and informing the development of novel diagnostic and therapeutic methods.
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Cancers (Basel) Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Suiza

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Cancers (Basel) Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Suiza